Accordingly, the Olaparib Expanded (Translational Breast Cancer Research Consortium) TBCRC 048 trial was conducted to assess whether patients with metastatic BC with germline mutation in HR-related genes other than BRCA1/2 or with somatic BRCA1/2 mutations could benefit from treatment with the PARPi olaparib [75]. This evidence concerns the gene BRCA1 and cancer.